A Humanized Preclinical in Vivo System to Predict the Immunotoxicity of Antibody Drug Candidates

September 29, 2021

James Keck, Ph.D., Senior Director of Innovation and Product Development, and Presidential Innovation Fellow, of The Jackson Laboratory speaks about a humanized preclinical in vivo system to predict the immunotoxicity of antibody drug candidates.

A Humanized Preclinical in Vivo System to Predict the Immunotoxicity of Antibody Drug Candidates

A New Way to Study Cytokine Release Syndrome

Poster: A Humanized In Vivo System to Predict Antibody-induced Cytokine Release Syndrome

CRS: FAQs

Choosing the Appropriate Humanized FcRn Mouse Model to Test the Pharmacokinetics of Antibody Therapeutics

The Humanized FcRn Platform: An Essential Tool for Preclinical PK Assessment of Therapeutic Antibody Candidates

JAX Guide: Assessing Antibody Pharmacokinetics Using the JAX FcRn Platform

Poster: Choosing the Appropriate Immune System- Humanized Mouse Model for Immuno-Modulatory Therapies

Human Immune System Engrafted Mice and Their Role in Human Antibody-Based Drug Development

Mode of Action of TCell Bispecific Antibodies and their Combinations with Checkpoint Inhibitors

Testing the Efficacy of Immuno-Modulatory Antibodies in Humanized Mice

The ABC’s of CAR T Cell Therapies